Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

222 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology.
Kaplan MA, Isikdogan A, Koca D, Kucukoner M, Gumusay O, Yildiz R, Dayan A, Demir L, Geredeli C, Kocer M, Arslan UY, Inal A, Akman T, Coskun U, Sener N, Inanc M, Elkiran ET, Ozdemir NY, Durnalı AG, Suner A, Alici S, Tarhan MO, Boruban C, Oksuzoglu B, Urakci Z. Kaplan MA, et al. Among authors: inal a. Breast Cancer. 2014 Nov;21(6):677-83. doi: 10.1007/s12282-013-0441-y. Epub 2013 Jan 19. Breast Cancer. 2014. PMID: 23335064 Clinical Trial.
Type 2 diabetes mellitus and prognosis in early stage breast cancer women.
Kaplan MA, Pekkolay Z, Kucukoner M, Inal A, Urakci Z, Ertugrul H, Akdogan R, Firat U, Yildiz I, Isikdogan A. Kaplan MA, et al. Among authors: inal a. Med Oncol. 2012 Sep;29(3):1576-80. doi: 10.1007/s12032-011-0109-4. Epub 2011 Nov 15. Med Oncol. 2012. PMID: 22083554
Gemcitabine alone versus combination of gemcitabine and cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a retrospective analysis of multicenter study.
Inal A, Kos FT, Algin E, Yildiz R, Dikiltas M, Unek IT, Colak D, Elkiran ET, Helvaci K, Geredeli C, Dane F, Balakan O, Kaplan MA, Durnali AG, Harputoglu H, Goksel G, Ozdemir N, Buyukberber S, Gumus M, Kucukoner M, Ozkan M, Uncu D, Benekli M, Isikdogan A. Inal A, et al. Neoplasma. 2012;59(3):297-301. doi: 10.4149/neo_2012_038. Neoplasma. 2012. PMID: 22329849
Adjuvant chemoradiation for gastric cancer: multicentric study of the Anatolian Society of Medical Oncology.
Kucukoner M, Isikdogan A, Arpaci E, Bilici M, Uncu D, Cetin B, Dane F, Inane M, Kaplan MA, Cayir K, Yetisyigit T, Ozdemir N, Inal A, Aksoy S, Alkis N, Tekin SB, Eroglu C, Turhal S, Benekli M, Buyukberber S. Kucukoner M, et al. Among authors: inal a. Hepatogastroenterology. 2012 Oct;59(119):2343-7. doi: 10.5754/hge11709. Hepatogastroenterology. 2012. PMID: 22389301
Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study.
Inal A, Kos FT, Algin E, Yildiz R, Berk V, Tugba Unek I, Colak D, Colak D, Kucukoner M, Tamer Elkiran E, Helvaci K, Geredeli C, Dane F, Balakan O, Ali Kaplan M, Gok Durnali A, Harputoglu H, Goksel G, Ozdemir N, Buyukberber S, Gumus M, Ozkan M, Benekli M, Isikdogan A; Anatolian Society Of Medical Oncology. Inal A, et al. J BUON. 2012 Jan-Mar;17(1):102-5. J BUON. 2012. PMID: 22517701
XELOX vs. FOLFOX4 as second line chemotherapy in advanced pancreatic cancer.
Berk V, Ozdemir N, Ozkan M, Aksoy S, Turan N, Inal A, Balakan O, Yasar N, Unal OU, Benekli M, Durnali A, Colak D, Sonmez OU. Berk V, et al. Among authors: inal a. Hepatogastroenterology. 2012 Nov-Dec;59(120):2635-9. doi: 10.5754/hge12181. Hepatogastroenterology. 2012. PMID: 22534542
222 results